{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Nexavar+%28BAY+43-9006%29+%28Sorafenib%29&page=8", "query": { "intervention": "Nexavar (BAY 43-9006) (Sorafenib)", "page": 8 }, "page_size": 10 }, "pagination": { "page": 8, "page_size": 10, "total_count": 327, "total_pages": 33, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Nexavar+%28BAY+43-9006%29+%28Sorafenib%29&page=9&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Nexavar+%28BAY+43-9006%29+%28Sorafenib%29&page=7&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T02:21:53.314Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01254890", "title": "Sorafenib and 5-Azacitidine in Acute Leukemia + Myelodysplastic Syndrome", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "Azacitidine", "type": "DRUG" }, { "name": "Sorafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2011-01", "completion_date": "2015-03", "has_results": true, "last_update_posted_date": "2016-05-06", "last_synced_at": "2026-10-14T02:21:53.314Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01254890" }, { "nct_id": "NCT00101413", "title": "BAY43-9006 - Phase II Study in Non-Small Cell Lung Carcinoma (NSCLC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cancer", "Carcinoma, Non-Small Cell Lung" ], "interventions": [ { "name": "Sorafenib (Nexavar, BAY43-9006)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 52, "start_date": "2004-04", "completion_date": "2008-04", "has_results": true, "last_update_posted_date": "2013-10-30", "last_synced_at": "2026-10-14T02:21:53.314Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00101413" }, { "nct_id": "NCT00375310", "title": "Phase I Study of Gemcitabine, Sorafenib and Radiotherapy in Patients With Unresectable Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreatic Cancer", "Adenocarcinoma of the Pancreas" ], "interventions": [ { "name": "Gemcitabine, Sorafenib", "type": "DRUG" }, { "name": "Radiotherapy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Indiana University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2006-09", "completion_date": "2014-11", "has_results": false, "last_update_posted_date": "2016-02-29", "last_synced_at": "2026-10-14T02:21:53.314Z", "location_count": 1, "location_summary": "Indianapolis, Indiana", "locations": [ { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00375310" }, { "nct_id": "NCT00767468", "title": "Sorafenib in Treating Patients With Locally Advanced or Metastatic Liver Cancer and Cirrhosis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Liver Cancer" ], "interventions": [ { "name": "sorafenib tosylate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2008-10", "completion_date": "2010-11", "has_results": false, "last_update_posted_date": "2012-05-23", "last_synced_at": "2026-10-14T02:21:53.314Z", "location_count": 2, "location_summary": "Chapel Hill, North Carolina • Durham, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00767468" }, { "nct_id": "NCT00494182", "title": "Sorafenib in Combination With Carboplatin and Paclitaxel in Treating Participants With Metastatic or Recurrent Head and Neck Squamous Cell Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Head and Neck Squamous Cell Carcinoma", "Metastatic Squamous Cell Carcinoma of the Hypopharynx", "Metastatic Squamous Cell Carcinoma of the Larynx", "Metastatic Squamous Cell Carcinoma of the Oral Cavity", "Metastatic Squamous Cell Carcinoma of the Oropharynx", "Recurrent Head and Neck Squamous Cell Carcinoma", "Recurrent Hypopharyngeal Squamous Cell Carcinoma", "Recurrent Laryngeal Squamous Cell Carcinoma", "Recurrent Oral Cavity Squamous Cell Carcinoma", "Recurrent Oropharyngeal Squamous Cell Carcinoma" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Sorafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2007-04-25", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-06-12", "last_synced_at": "2026-10-14T02:21:53.314Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00494182" }, { "nct_id": "NCT00131989", "title": "Sorafenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Acute Basophilic Leukemia", "Adult Acute Eosinophilic Leukemia", "Adult Acute Megakaryoblastic Leukemia (M7)", "Adult Acute Minimally Differentiated Myeloid Leukemia (M0)", "Adult Acute Monocytic Leukemia (M5b)", "Adult Acute Myeloblastic Leukemia With Maturation (M2)", "Adult Acute Myeloblastic Leukemia Without Maturation (M1)", "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Del(5q)", "Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Adult Acute Myelomonocytic Leukemia (M4)", "Adult Erythroleukemia (M6a)", "Adult Pure Erythroid Leukemia (M6b)", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Myeloid Leukemia" ], "interventions": [ { "name": "sorafenib tosylate", "type": "DRUG" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2005-06", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-01-09", "last_synced_at": "2026-10-14T02:21:53.314Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00131989" }, { "nct_id": "NCT01033240", "title": "CS1008- in Combination With Sorafenib Compared to Sorafenib Alone in Subjects With Advanced Liver Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Hepatocellular Carcinoma", "Liver Cancer", "Hepatic Cancer", "Liver Neoplasms" ], "interventions": [ { "name": "CS-1008 2 mg/kg", "type": "DRUG" }, { "name": "Sorafenib", "type": "DRUG" }, { "name": "CS-1008 6/2 mg/kg", "type": "DRUG" }, { "name": "CS-1008 6/6 mg/kg", "type": "DRUG" }, { "name": "CS-1008 4 mg/kg", "type": "DRUG" }, { "name": "CS-1008 6 mg/kg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 172, "start_date": "2010-07-09", "completion_date": "2013-09-09", "has_results": true, "last_update_posted_date": "2021-04-08", "last_synced_at": "2026-10-14T02:21:53.314Z", "location_count": 4, "location_summary": "Los Angeles, California • Washington D.C., District of Columbia • New York, New York + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "New York", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01033240" }, { "nct_id": "NCT00573755", "title": "Sorafenib and Letrozole, Anastrozole, or Exemestane in Treating Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Metastatic Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "anastrozole", "type": "DRUG" }, { "name": "exemestane", "type": "DRUG" }, { "name": "letrozole", "type": "DRUG" }, { "name": "sorafenib tosylate", "type": "DRUG" }, { "name": "placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "FEMALE", "summary": "18 Years to 120 Years · Female only" }, "enrollment_count": 4, "start_date": "2007-12", "completion_date": "2013-04", "has_results": true, "last_update_posted_date": "2016-02-05", "last_synced_at": "2026-10-14T02:21:53.314Z", "location_count": 3, "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00573755" }, { "nct_id": "NCT00119249", "title": "Sorafenib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Stage III Melanoma", "Stage IV Melanoma" ], "interventions": [ { "name": "sorafenib tosylate", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 74, "start_date": "2005-06", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-01-15", "last_synced_at": "2026-10-14T02:21:53.314Z", "location_count": 1, "location_summary": "The Bronx, New York", "locations": [ { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00119249" }, { "nct_id": "NCT00828594", "title": "Global Study Looking at the Combination of RAD001 and Sorafenib to Treat Patients With Advanced Hepatocellular Carcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hepatocellular Carcinoma" ], "interventions": [ { "name": "RAD001", "type": "DRUG" }, { "name": "RAD001, sorafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 130, "start_date": "2008-12", "completion_date": "2011-06", "has_results": false, "last_update_posted_date": "2013-04-11", "last_synced_at": "2026-10-14T02:21:53.314Z", "location_count": 3, "location_summary": "Duarte, California • Los Angeles, California • Durham, North Carolina", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00828594" } ] }